 |
인쇄하기
취소
|
Kwangdong to market new radiosensitizer in 2012
Kwangdong Pharm says it has signed an exclusive lisensing agreement with China-based Shandong Luye Pharmaceutical (SDLY) to develop and market a novel radiosensitizer “CMNa” in Korea.
CMNa is a new nitroimidazole compound, which was designed and synthesized, and studied by Chinese scientists since 1984. It is effective on enhancing tumor sensitivity to radiation and chemotherapy with only s...
CMNa is a new nitroimidazole compound, which was designed and synthesized, and studied by Chinese scientists since 1984. It is effective on enhancing tumor sensitivity to radiation and chemotherapy with only s...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.